GlassScriptPhysician profile
Maria Lugo
NPI 1669488375
$2,216.09
in general payments reported to CMS, 2019-2025
25 companies · $598 in 2025
The $598 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $77.67 · 2022: $112 · 2023: $324 · 2024: $927 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,849.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $492.78 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $358.13 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $244.26 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $145.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $124.99 | 2024 | Vyepti |
| Axsome Therapeutics, INC. | $121.85 | 2025 | Auvelity |
| Lilly USA, LLC | $121.30 | 2019-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.69 | 2024 | Caplyta |
| Merck Sharp & Dohme LLC | $80.32 | 2019-2025 | Gardasil 9, Capvaxive |
| Pfizer INC. | $67.10 | 2022-2025 | |
| Glaxosmithkline, LLC. | $59.16 | 2019-2024 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.59 | 2019-2024 | Jardiance |
| Acera Surgical, INC. | $34.25 | 2025 | Restrata Wound Matrix |
| Edwards Lifesciences Corporation | $31.06 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $29.52 | 2024-2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $25.11 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $20.07 | 2025 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $18.95 | 2023 | Uptravi, Opsumit |
| Ars Pharmaceuticals Operations, INC. | $17.00 | 2025 | Neffy |
| Pharmacosmos Therapeutics INC. | $15.15 | 2023 | Monoferric |
| Amarin Pharma, INC. | $14.82 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $13.69 | 2024 | Exparel, Zilretta, Iovera |
| Takeda Pharmaceuticals U.S.A., INC. | $13.57 | 2019 | |
| Dynavax Technologies Corporation | $12.54 | 2023 | Heplisav-B |
| Genentech USA, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Lugo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.